Skip to main content
LMRI
NASDAQ Industrial Applications And Services

Lumexa 10-Q: Q3 Net Income $7.2M, But Material Weaknesses Persist and Controls Not Effective

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$15.95
Mkt Cap
$1.532B
52W Low
$6.45
52W High
$19.45
52W Position info
147% above low
Off High info
18% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

LMRI has more than doubled off its 52-week low of $6.45 on elevated volume (2.2× avg).

Summary

Lumexa's Q3 10-Q repeats the already-released $7.2 million net income but newly details that material weaknesses in internal controls remain unremediated (disclosure controls not effective) and that a data-breach class action is in court-ordered mediation with no loss reserve recorded.


Key Events · Earnings and Guidance · LMRI

  • Q3 Earnings Repeat, Cash Flow Improves

    Q3 2026 net income was $7.2 million versus a $3.5 million loss a year ago, on total revenues of $272.0 million. Nine-month operating cash flow was $70.5 million provided versus roughly breakeven a year ago.

  • Material Weaknesses Remain Unremediated

    Management concluded disclosure controls and procedures were not effective as of September 30, 2026 because the previously identified material weaknesses in internal control over financial reporting were not remediated.

  • Data-Breach Class Action in Mediation

    The consolidated class action In re Lumexa Imaging Data Breach Litigation was stayed by court order on August 31, 2026 to allow mediation; the company says an unfavorable outcome is reasonably possible and has recorded no loss contingency.

  • Debt Refinancing Cuts Interest Cost

    Interest expense fell to $48.2 million for the nine months from $90.5 million a year ago after the December 2025 refinancing; total debt obligations were $848.5 million at September 30, 2026, with $90.0 million of cash.


Analysis · LMRI · Industrial Applications And Services

The headline numbers were already out on November 10 — Q3 net income of $7.2 million versus a $3.5 million loss a year ago, on revenue of $272.0 million. What is new in the 10-Q is the control and legal picture: management concluded disclosure controls were not effective as of September 30, 2026 because the previously disclosed material weaknesses in internal control over financial reporting were not remediated, and the company disclosed a consolidated data-breach class action that was stayed on August 31, 2026 to allow mediation, with an unfavorable outcome reasonably possible and no loss contingency recorded. Those two items are why this filing matters beyond the earnings repeat — they are governance and litigation risk that the earnings release did not carry. The underlying business is improving: nine-month operating cash flow swung to $70.5 million provided from roughly breakeven a year ago, helped by interest expense falling to $48.2 million from $90.5 million after the December 2025 refinancing.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LMRI was trading at $15.95 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $6.45 to $19.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LMRI - Latest Insights

LMRI
Nov 10, 2026, 4:08 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $13.92
Real-time Price: $15.95 info
Change: +$2.03 (+15%) info
Market Cap: $1.532B info
LMRI
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.92
Real-time Price: $15.95 info
Change: +$2.03 (+15%) info
Market Cap: $1.532B info
LMRI
Aug 13, 2026, 2:54 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.30
Real-time Price: $15.95 info
Change: +$3.65 (+30%) info
Market Cap: $1.532B info
LMRI
Aug 12, 2026, 4:18 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $12.00
Real-time Price: $15.95 info
Change: +$3.95 (+33%) info
Market Cap: $1.532B info
LMRI
Aug 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.06
Real-time Price: $15.95 info
Change: +$3.89 (+32%) info
Market Cap: $1.532B info